Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma. Issue 6 (22nd April 2015)

• Record Type: Journal Article
• Authors: Nakazawa, Atsuko; Haga, Chizuko; Ohira, Miki; Okita, Hajime; Kamijo, Takehiko; Nakagawara, Akira
• Is Part Of: Cancer science. Volume 106:Issue 6(2015:Jun.)
• Page Start: 766
• Page End: 771
• Publication Date: 2015-04-22
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.12665
• Languages: English
• ISSNs: 1347-9032

Abstract

<abstract abstract-type="main" id="cas12665-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The International Neuroblastoma Pathology Classification (INPC) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology (FH) and unfavorable histology (UH). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses (GGP), as well as the correlation of FH tumor and whole gains and/or losses (GGW), was statistically significant. Both UH and GGP were late‐onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [OS], 43.1% and 42.4%, respectively). In contrast, both FH and GGW were early‐onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis (OS, 88.6% and 87.1%, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW. Overall survival was not significantly different among the genomic groups in FH; however, it was inferior in UH with GGP. In UH with a single copy <italic>MYCN</italic>, genomic subgroups GGP2s (both 1p and 11q losses) and GGP3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP4s (no partial 1p and 11q loss). As INPC and <italic>MYCN</italic> amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of <italic>MYCN</italic>.</p> </abstract>